What is the recommended management for a geriatric patient with confirmed respiratory syncytial virus infection?

Geriatric RSV infection (Texas) — What to do now

Bold recommendation: Admit or closely monitor any ≥75-year-old or high‑risk geriatric with confirmed RSV who has LRT involvement, hypoxemia, or decompensating comorbidities; provide supportive care only (no routine antivirals), avoid unnecessary antibiotics, and arrange post‑recovery RSV vaccination when eligible to reduce future morbidity, mortality, and loss of function. 1

1) Triage and disposition (prioritize morbidity/mortality/QOL)

• Admit if any of the following:
  • Age ≥75 OR residence in nursing home, frailty, dementia, or major comorbidity (COPD/asthma, CHF/CAD, CKD, diabetes, cirrhosis, immunocompromise), plus LRT disease or clinical instability (SpO2 < 92%, RR > 24, hypotension, altered mentation, dehydration, acute functional decline). These factors predict higher hospitalization, longer LOS, and increased 30–90‑day mortality and functional loss in older adults with RSV 1.
  • Need for oxygen, inability to maintain PO intake, or new/worsening heart–lung decompensation (e.g., AECOPD, HF) 1.
• Consider observation/ED return precautions if 60–74, stable vitals, no hypoxemia, mild URT symptoms only, and reliable follow‑up.

2) Treatment (there is no proven routine anti‑RSV drug for adults)

• Supportive therapy only:
  • Oxygen to target SpO2 ≥ 92%; bronchodilators for reversible bronchospasm; antipyretics; cautious fluids; manage AECOPD/HF per standards (e.g., diuretics if HF overload, short steroid course if COPD exacerbation) 2.
  • VTE prophylaxis if admitted and reduced mobility.
• Antivirals/monoclonals:
  • Do NOT use palivizumab or routine antivirals in adults; evidence does not support benefit and guidelines emphasize prevention over treatment in older adults 1, 2.
  • Ribavirin ± IVIG is reserved for select hematologic/HSCT patients; not for general geriatric care due to limited evidence and toxicity/logistics 3.
• Antibiotics:
  • Withhold empiric antibiotics unless there is clear bacterial evidence (lobar consolidation with focal exam, sepsis, positive cultures). Up to ~40–98% of older RSV patients receive antibiotics despite ≤20% confirmed coinfection—de‑escalate once RSV confirmed and no bacterial source to avoid harm and resistance 4.
• Comorbidity management:
  • Monitor for arrhythmias, ischemia, AKI; these predict worse outcomes and are common in hospitalized older adults with RSV 5.

3) Monitoring and escalation

• Reassess daily (or sooner if outpatient) for:
  • Worsening hypoxemia, rising work of breathing, new infiltrates, hemodynamic instability, acute delirium, or inability to ambulate/feed; low threshold for escalation/ICU in the very old (≥75) or immunocompromised given higher short‑term mortality and prolonged functional decline risk 1, 5.

4) Post‑acute recovery and QOL preservation

• Early mobilization, PT/OT, and recovery plan to prevent persistent functional loss, which is common after RSV hospitalization in older adults 1.
• Ensure up‑to‑date influenza, COVID‑19, and pneumococcal vaccination to reduce future respiratory morbidity.

5) Secondary prevention: vaccinate after recovery (not during acute illness)

• Timing: vaccinate once clinically recovered (usually ≥2–4 weeks after illness) and before/early in RSV season (prefer Sept–Nov) 1.
• Who in the US should get RSV vaccine (single dose):
  • All adults ≥75 years, and adults 60–74 with increased risk (chronic cardiac/pulmonary disease, ESRD, diabetes, neuro/neuromuscular disease, chronic liver/hematologic disease, severe obesity, moderate–severe immunocompromise, or nursing‑home residence) per ACIP‑aligned recommendations summarized in 2025 position guidance 1.
• Why vaccinate (outcomes that matter):
  • Older adults (especially ≥75) have high hospitalization and 30–90‑day mortality; RSV vaccination reduces RSV‑LRTD and severe LRTD across multiple seasons, supporting lower future morbidity/mortality and functional decline 1.
  • Highest‑quality, recent guideline synthesis reports sustained efficacy and acceptable safety for available vaccines in ≥60‑year‑olds, including those with comorbidities 1.

6) Common pitfalls (avoid)

• Starting or continuing antibiotics once RSV is confirmed without bacterial evidence—stop to reduce harm 4.
• Searching for adult indications for palivizumab or routine antivirals—none for typical geriatric patients 3, 2.
• Delaying vaccination after recovery—schedule before next season; can coadminister with influenza vaccine if timing aligns 1.
• Underestimating functional decline risk—arrange rehab and follow‑up; this impacts long‑term QOL and mortality 1.

7) One‑page algorithm (practical)

• Confirmed RSV in ≥60 years:
  • Assess severity/risk (≥75, nursing home/frailty/dementia, COPD/CHF/CKD/DM/immunocompromise; SpO2, RR, BP, mental status, hydration, function).
  • Admit if hypoxemia/LRTD/instability/high‑risk; otherwise close follow‑up in 24–48 h.
  • Treat supportively; manage comorbid exacerbations; avoid routine antibiotics; no adult monoclonals/antivirals.
  • Monitor for cardiac/renal complications; escalate early if worsening.
  • After recovery: vaccinate per ACIP‑aligned criteria; prefer Sept–Nov; coadminister with flu if due. Focus on rehab to preserve function/QOL. 1, 2, 5